Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 282.00
Bid: 284.00
Ask: 288.00
Change: 2.00 (0.71%)
Spread: 4.00 (1.408%)
Open: 278.00
High: 286.00
Low: 278.00
Prev. Close: 280.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

Mon, 14th Nov 2022 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Hutchmed (China) Ltd, up 13% at 184.96 pence, 12-month range 1.30p - 194.00p. The Hong Kong-based biopharmaceutical company reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. The drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase three study in 703 patients, which the firm explains is clinically meaningful. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

----------

Midatech Pharma PLC, up 7.2% at 6.49 pence, 12-month range 6.00p - 24.63p. Enrols the first patient into its phase one study of MTX-110 in recurrent glioblastoma, a type of cancer that appears in the brain or spinal cord. The study is an open-label, dose escalation study to assess the feasibility and safety of intermittent infusions of MTX-100. Cardiff-based biotechnology firm Midatech says it previously reported "encouraging results" from a phase one study of MTX-110 in diffuse intrinsic pontine glioma, a type of tumour that is located on the brain stem.

----------

SRT Marine Systems PLC, up 7.6% at 48.95 pence, 12-month range 23.60p - 55.00p. The maritime surveillance, analytics and management systems developer reports a steep increase in interim revenue as it swings to a pretax profit of GBP2.1 million from a loss of GBP3.1 million. In the six months to September 30, SRT Marine Systems reports revenue of GBP18.8 million, multiplied from GBP4.7 million the previous year. This, it adds, is despite ongoing component supply issues. Chief Executive Simon Tuckers expects this strong performance to continue going forward as long-term demand stays robust.

----------

AIM - LOSERS

----------

Tremor International Ltd, down 26% at 281.00 pence, 12-month range 2.90p - 330.60p. Swings to a total comprehensive IFRS loss of USD5.2 million in the three months ended September 30, from a profit of USD10.2 million the previous year. Revenue in the quarter drops 19% year-on-year to USD70.9 million from USD87.0 million. Despite the drop in profit and revenue, Tremor says it remains "well-positioned" to benefit from "anticipated industry secular growth trends" which it expects to help mitigate potential negative effects. Full-year adjusted earnings before interest, taxation, depreciation, and amortization is expected at USD140 million.

----------

Shanta Gold Ltd, down 12% at 9.60 pence, 12-month range 6.50p - 14.00p. Three companies which previously expressed interest in the East Africa-focused gold producer, developer and explorer say they do not intend to make an offer for the firm. In October, Shanta received approaches from Shandong Gold Group Co Ltd, Yintai Gold Co Ltd and Chaarat Gold Holdings Ltd. These companies have since decided not to proceed with an offer. Nonetheless, Shanta says it continues to believe in the strength of its business and the potential of its portfolio.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 Sep 2020 14:13

Hutchison Chi-Med begins latest trial of fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe and Japan.

Read more
3 Sep 2020 21:27

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

IN BRIEF: Hutchison China Initiates Phase II Trial Of HMPL-453

Read more
10 Aug 2020 11:04

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

IN BRIEF: Hutchison Chi-Med Plans Surufatnib Marketing Application

Read more
30 Jul 2020 17:56

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

IN BRIEF: Hutchison China Interim Loss Widens Despite Revenue Growth

Read more
28 Jul 2020 19:48

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

IN BRIEF: Hutchison China Amends License Agreement With Eli Lilly

Read more
24 Jul 2020 15:45

Hutchison Chi-Med begins phase 1 study of 'HMPL-306'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.

Read more
24 Jul 2020 14:33

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Chi-Med Trials Dual Inhibitor For Hematological Cancer

Read more
23 Jul 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
23 Jul 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
25 Jun 2020 15:08

Hutchison China Gets USD100 Million From US Private Equity Firm

Hutchison China Gets USD100 Million From US Private Equity Firm

Read more
18 Jun 2020 16:46

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

IN BRIEF: Hutchison China Gets US FDA Fast Track For Cancer Drug

Read more
18 Jun 2020 09:18

Hutchison Chi-Med gets FDA fast track approval for fruquintinib

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the development of 'fruquintinib'.

Read more
9 Jun 2020 14:06

Hutchison Chi-Med venture to surrender unused land in Guangzhou

(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with Guangzhou Baiyunshan Pharmaceutical Holdings - has agreed the planned return of its remaining 34 years land-use rights on its 30,000 square metre unused site in Tong He Town with the Guangzhou government.

Read more
9 Jun 2020 13:25

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Read more
4 Jun 2020 13:19

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

UK TRADING UPDATE SUMMARY: Open Orphan Launches Covid Testing Service

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.